Released: 17-Sep-2014 10:00 AM EDT Source Newsroom: Alzforum Contact Information

Available for logged-in reporters only

Newswise Rising to fame from humble beginnings in bacteria, the CRISPR gene editing system has taken the biomedical field by storm. Using an ever-evolving genetic toolbox to change, turn off, turn on, add, or delete genes, scientists can tinker with any region of the genome. The technology may one day allow clinicians to correct mutations in genetic diseases or deliver therapeutic genes to mend damaged cells or kill cancerous ones, scientists predict.

Neuroscientists have adopted CRISPR to neurons, both in a dish and in living animals, and they have set their sights on using the technology to treat neurodegenerative diseases such as ALS, Parkinsons, Huntingtons, and Alzheimers. In a two-part series, Alzforum explains the CRISPR technology and its first neuroscience forays (Part I), and delves into how scientists will engineer transgenic animals and perhaps treat disease through CRISPR gene therapy (Part II).

About Alzforum: Founded in 1996, Alzforum is a dynamic, Web-based scientific community dedicated to understanding Alzheimer's disease and related disorders. Access to the website is free to all. Our editorial priorities are as diverse as the needs of the research community. The website reports on the latest scientific findings from basic research to clinical trials, creates and maintains public databases of essential research data and reagents, and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across the numerous disciplines that can contribute to the global effort to cure Alzheimer's disease. The Alzforum team of professional science writers and editors, information technology experts, Web developers, and producers all work closely with our distinguished Advisory Board to ensure a high quality of information and services. We very much welcome our readers' participation in all aspects of the website.

Alzforum is developed and operated by the Biomedical Research Forum (BRF) LLC. BRF is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies. The Alzforum website does not endorse any specific product or scientific approach.

Read the rest here:
Neuroscientists Get Busy in the CRISPR Kitchen--What Will They Cook Up?

Comments are closed.